Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

Approaches to deplete persistent HIV infection are needed. We investigated the combined impact of the latency reversing agent vorinostat (VOR) and AGS-004, an autologous dendritic cell immunotherapeutic, on the HIV reservoir. HIV+, stably treated participants in whom resting CD4(+) T cell-associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Gay, Cynthia L., Kuruc, Joann D., Falcinelli, Shane D., Warren, Joanna A., Reifeis, Sarah A., Kirchherr, Jennifer L., James, Katherine S., Dewey, Morgan G., Helms, Alyson, Allard, Brigitte, Stuelke, Erin, Gamble, Alicia, Plachco, Ana, Gorelick, Robert J., Eron, Joseph J., Hudgens, Michael, Garrido, Carolina, Goonetilleke, Nilu, DeBenedette, Mark A., Tcherepanova, Irina Y., Nicolette, Charles A., Archin, Nancie M., Margolis, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083965/
https://www.ncbi.nlm.nih.gov/pubmed/32198428
http://dx.doi.org/10.1038/s41598-020-61878-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083965/
https://www.ncbi.nlm.nih.gov/pubmed/32198428
http://dx.doi.org/10.1038/s41598-020-61878-3

Ejemplares similares